MX2010007525A - Derivados de indolil-piridona que tienen actividad inhibitoria de la cinasa 1 de punto de control. - Google Patents
Derivados de indolil-piridona que tienen actividad inhibitoria de la cinasa 1 de punto de control.Info
- Publication number
- MX2010007525A MX2010007525A MX2010007525A MX2010007525A MX2010007525A MX 2010007525 A MX2010007525 A MX 2010007525A MX 2010007525 A MX2010007525 A MX 2010007525A MX 2010007525 A MX2010007525 A MX 2010007525A MX 2010007525 A MX2010007525 A MX 2010007525A
- Authority
- MX
- Mexico
- Prior art keywords
- alkoxy
- hydroxy
- alkyl
- hydrogen
- optionally substituted
- Prior art date
Links
- 108010019244 Checkpoint Kinase 1 Proteins 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- NRGVEGWSRITVOR-UHFFFAOYSA-N 3-(1h-indol-2-yl)-1h-pyridin-2-one Chemical class OC1=NC=CC=C1C1=CC2=CC=CC=C2N1 NRGVEGWSRITVOR-UHFFFAOYSA-N 0.000 title 1
- 102000006459 Checkpoint Kinase 1 Human genes 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 2
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 abstract 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 2
- -1 hydroxy, methyl Chemical group 0.000 abstract 2
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se describen los compuestos de la fórmula (I) que tiene actividad inhibitoria de la cinasa 1 del punto de control (CHK1): R1, R2, R5 y R6 son independientemente seleccionados de hidrógeno, hidroxilo, metilo, trifluorometilo, hidroximetilo, metoxi, trifluorometoxi, metilamino y dimetilamino; R3 y R4, son independientemente seleccionados de hidrógeno, hidroxilo, alquilo de 1 a 3 átomos de carbono, fluoro-(alquilo de 1 a 3 átomos de carbono), hidroxi-(alquilo de 1 a 3 átomos de carbono), alcoxi de 1 a 3 átomos de carbono, fluoro-(alcoxi de 1 a 3 átomos de carbono), hidroxi-(alcoxi de 1 a 3 átomos de carbono), -N(R11)-R12, -Alk-N(R11)-R12, o -C-Alk-N(R11)-R12, -C(=0)OH, carboxi-(alquilo de 1 a 3 átomos de carbono), o -C(=0)-NH-R13 Alk es un radical alquileno de 1 a 6 átomos de carbono, divalente, de cadena lineal o ramificada; R7 y R8 son independientemente seleccionados de hidrógeno, hidroxilo, o alcoxi de 1 a 3 átomos de carbono; X es un radical alquileno de 1 a 3 átomos de carbono, divalente, de cadena lineal, opcionalmente sustituido sobre uno o más carbonos con R9 y/o R10 W se selecciona de -C(=O)-N(-R16)- o -N(-R17)-C(=0)-; Y es hidrógeno, alquilo de 1 a 3 átomos de carbono, alcoxi de 1 a 3 átomos de carbono, o halo; y Q se selecciona de fenilo opcionalmente sustituido, ciclohexilo opcionalmente sustituido o un anillo heteroarilo monocíclico de 6 miembros opcionalmente sustituido.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0801090.2A GB0801090D0 (en) | 2008-01-22 | 2008-01-22 | New chemical compounds |
| GBGB0818695.9A GB0818695D0 (en) | 2008-10-11 | 2008-10-11 | New chemical compounds |
| PCT/GB2009/000149 WO2009093012A1 (en) | 2008-01-22 | 2009-01-20 | Indolyl- pyridone derivatives having checkpoint kinase 1 inhibitory activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010007525A true MX2010007525A (es) | 2010-08-18 |
Family
ID=40377594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010007525A MX2010007525A (es) | 2008-01-22 | 2009-01-20 | Derivados de indolil-piridona que tienen actividad inhibitoria de la cinasa 1 de punto de control. |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US8916591B2 (es) |
| EP (1) | EP2294065B1 (es) |
| JP (1) | JP5386508B2 (es) |
| CN (1) | CN101970424B (es) |
| AU (1) | AU2009207478B2 (es) |
| BR (1) | BRPI0906495B8 (es) |
| CA (1) | CA2712959C (es) |
| DK (1) | DK2294065T3 (es) |
| EA (1) | EA021464B1 (es) |
| ES (1) | ES2461799T3 (es) |
| IL (1) | IL206808A (es) |
| MX (1) | MX2010007525A (es) |
| NZ (1) | NZ586756A (es) |
| PL (1) | PL2294065T3 (es) |
| PT (1) | PT2294065E (es) |
| WO (1) | WO2009093012A1 (es) |
| ZA (1) | ZA201005210B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2712959C (en) | 2008-01-22 | 2015-06-23 | Vernalis (R & D) Ltd | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity |
| GB0912499D0 (en) * | 2009-07-18 | 2009-08-26 | Vernalis R&D Ltd | Indopyl-pyridone derivatives |
| KR101464060B1 (ko) | 2010-04-07 | 2014-11-20 | 에프. 호프만-라 로슈 아게 | 피라졸-4-일-헤테로사이클릴-카복사마이드 화합물 및 사용 방법 |
| EP2463289A1 (en) * | 2010-11-26 | 2012-06-13 | Almirall, S.A. | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors |
| EP2760857A1 (en) | 2011-09-27 | 2014-08-06 | F.Hoffmann-La Roche Ag | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use |
| GB201201566D0 (en) | 2012-01-30 | 2012-03-14 | Vernalis R&D Ltd | New chemical compounds |
| WO2015013579A1 (en) | 2013-07-26 | 2015-01-29 | Update Pharma Inc. | Compositions to improve the therapeutic benefit of bisantrene |
| MY182181A (en) | 2015-01-28 | 2021-01-18 | Bayer Pharma AG | 4h-pyrrolo[3,2-c]pyridin-4-one derivatives |
| KR20200101398A (ko) | 2017-12-19 | 2020-08-27 | 브리스톨-마이어스 스큅 컴퍼니 | Tlr 억제제로서 유용한 아미드 치환된 인돌 화합물 |
| KR20210038911A (ko) * | 2018-07-24 | 2021-04-08 | 에피자임, 인코포레이티드 | Smarca2 길항제로서 유용한 피리딘-2-온 화합물 |
| US10253606B1 (en) | 2018-07-27 | 2019-04-09 | Upwing Energy, LLC | Artificial lift |
| US10787873B2 (en) | 2018-07-27 | 2020-09-29 | Upwing Energy, LLC | Recirculation isolator for artificial lift and method of use |
| US10280721B1 (en) | 2018-07-27 | 2019-05-07 | Upwing Energy, LLC | Artificial lift |
| US10370947B1 (en) * | 2018-07-27 | 2019-08-06 | Upwing Energy, LLC | Artificial lift |
| CN110857293B (zh) * | 2018-08-24 | 2023-01-10 | 药捷安康(南京)科技股份有限公司 | 一种新型的喹啉衍生物抑制剂 |
| US11686161B2 (en) | 2018-12-28 | 2023-06-27 | Upwing Energy, Inc. | System and method of transferring power within a wellbore |
| EP4036086A1 (en) * | 2019-09-24 | 2022-08-03 | Transthera Sciences (Nanjing), Inc. | Heterocyclic derivative and use thereof |
| WO2023250141A2 (en) * | 2022-06-24 | 2023-12-28 | Enalare Therapeutics Inc. | Methods of treating neurological ventilatory insufficiency |
| CN115594634B (zh) * | 2022-10-26 | 2024-10-01 | 浙江工业大学 | 一种连续化制备4-硝基吡唑的新工艺 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL373300A1 (en) * | 2001-03-28 | 2005-08-22 | Bristol-Myers Squibb Company | Novel tyrosine kinase inhibitors |
| AU2002334217B2 (en) | 2001-10-26 | 2008-07-03 | Aventis Pharmaceuticals Inc. | Benzimidazoles and analogues and their use as protein kinases inhibitors |
| US20050256157A1 (en) * | 2002-08-23 | 2005-11-17 | Chiron Corporation | Combination therapy with CHK1 inhibitors |
| CN1798726A (zh) | 2003-06-05 | 2006-07-05 | 麦克公司 | 取代吲哚及一种制备取代吲哚的方法 |
| TWI372050B (en) * | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
| WO2007084135A2 (en) * | 2005-01-28 | 2007-07-26 | Merck & Co., Inc. | Inhibitors of checkpoint kinases |
| EP1891048A1 (en) * | 2005-06-11 | 2008-02-27 | Vernalis (R&D) Limited | Pyrazole-substituted benzimidazole derivatives for use in the treatment of cancer and autoimmune disorders |
| WO2008007122A2 (en) * | 2006-07-14 | 2008-01-17 | Astex Therapeutics Limited | Combinations of pyrazole derivatives for the inhibition of cdks and gsk's |
| WO2008025526A1 (en) | 2006-08-31 | 2008-03-06 | F. Hoffmann-La Roche Ag | Indole derivatives, their manufacture and use as pharmaceutical agents |
| CA2712959C (en) | 2008-01-22 | 2015-06-23 | Vernalis (R & D) Ltd | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity |
| KR20120023091A (ko) * | 2009-05-15 | 2012-03-12 | 노파르티스 아게 | 5-피리딘-3-일-1,3-디히드로-인돌-2-온 유도체, 및 알도스테론 신타제 및/또는 ｃｙｐ11ｂ1의 조절제로서의 그의 용도 |
-
2009
- 2009-01-20 CA CA2712959A patent/CA2712959C/en not_active Expired - Fee Related
- 2009-01-20 ES ES09704645T patent/ES2461799T3/es active Active
- 2009-01-20 CN CN200980103188XA patent/CN101970424B/zh not_active Expired - Fee Related
- 2009-01-20 PT PT09704645T patent/PT2294065E/pt unknown
- 2009-01-20 AU AU2009207478A patent/AU2009207478B2/en not_active Ceased
- 2009-01-20 WO PCT/GB2009/000149 patent/WO2009093012A1/en active Application Filing
- 2009-01-20 MX MX2010007525A patent/MX2010007525A/es active IP Right Grant
- 2009-01-20 EA EA201001197A patent/EA021464B1/ru not_active IP Right Cessation
- 2009-01-20 JP JP2010543556A patent/JP5386508B2/ja not_active Expired - Fee Related
- 2009-01-20 EP EP20090704645 patent/EP2294065B1/en not_active Not-in-force
- 2009-01-20 US US12/812,791 patent/US8916591B2/en not_active Expired - Fee Related
- 2009-01-20 PL PL09704645T patent/PL2294065T3/pl unknown
- 2009-01-20 DK DK09704645T patent/DK2294065T3/da active
- 2009-01-20 NZ NZ586756A patent/NZ586756A/en not_active IP Right Cessation
- 2009-01-20 BR BRPI0906495A patent/BRPI0906495B8/pt not_active IP Right Cessation
-
2010
- 2010-07-05 IL IL206808A patent/IL206808A/en active IP Right Grant
- 2010-07-21 ZA ZA2010/05210A patent/ZA201005210B/en unknown
-
2014
- 2014-11-10 US US14/536,764 patent/US9604975B2/en active Active
-
2017
- 2017-02-08 US US15/427,457 patent/US20170298043A1/en not_active Abandoned
-
2018
- 2018-04-25 US US15/962,306 patent/US10696652B2/en not_active Expired - Fee Related
-
2020
- 2020-05-28 US US16/886,276 patent/US20200361905A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NZ586756A (en) | 2012-04-27 |
| JP5386508B2 (ja) | 2014-01-15 |
| BRPI0906495A2 (pt) | 2015-07-14 |
| ES2461799T3 (es) | 2014-05-21 |
| CN101970424A (zh) | 2011-02-09 |
| ZA201005210B (en) | 2011-03-30 |
| WO2009093012A1 (en) | 2009-07-30 |
| IL206808A0 (en) | 2010-12-30 |
| PL2294065T3 (pl) | 2014-11-28 |
| US10696652B2 (en) | 2020-06-30 |
| CN101970424B (zh) | 2013-06-12 |
| EA201001197A1 (ru) | 2011-04-29 |
| US8916591B2 (en) | 2014-12-23 |
| AU2009207478B2 (en) | 2013-11-21 |
| BRPI0906495B8 (pt) | 2021-05-25 |
| US20110021498A1 (en) | 2011-01-27 |
| BRPI0906495B1 (pt) | 2020-11-10 |
| CA2712959A1 (en) | 2009-07-30 |
| EA021464B1 (ru) | 2015-06-30 |
| US20150099736A1 (en) | 2015-04-09 |
| DK2294065T3 (da) | 2014-04-28 |
| US20180244652A1 (en) | 2018-08-30 |
| CA2712959C (en) | 2015-06-23 |
| EP2294065A1 (en) | 2011-03-16 |
| EP2294065B1 (en) | 2014-03-19 |
| IL206808A (en) | 2015-08-31 |
| JP2011510055A (ja) | 2011-03-31 |
| BRPI0906495A8 (pt) | 2015-10-06 |
| US20170298043A1 (en) | 2017-10-19 |
| PT2294065E (pt) | 2014-05-15 |
| US20200361905A1 (en) | 2020-11-19 |
| US9604975B2 (en) | 2017-03-28 |
| AU2009207478A1 (en) | 2009-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2010007525A (es) | Derivados de indolil-piridona que tienen actividad inhibitoria de la cinasa 1 de punto de control. | |
| CR9830A (es) | Compuestos de amino-5-[4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de la b-secretasa | |
| MX2009012222A (es) | Dihidroquinonas y dihidronaftiridinas como inhibidores de las quinasas c-jun-n-terminales. | |
| NO20074057L (no) | 2,4-Diaminopyridopyrimidinderivater og deres anvendelse som mTOR-inhibitorer | |
| TW200637819A (en) | Indoles useful in the treatment of inflammation | |
| WO2007081571A3 (en) | Cetp inhibitors | |
| TW200637818A (en) | Indoles useful in the treatment of inflammation | |
| EA200601896A1 (ru) | Производные пролина и их применение в качестве ингибиторов дипептидилпептидазы iv | |
| CR7680A (es) | Un nuevo proceso para la sintesis de agomelatina | |
| IL198116A0 (en) | Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors | |
| UA84460C2 (ru) | Применение сульфонилкарбамидов для борьбы с нежелательным ростом растений в культурах бобовых | |
| CR9244A (es) | AMINO-IMIDAZOLONAS PARA LA INHIBICION DE ß-SECRETASA | |
| RS52999B (en) | BIS (AMIDIDA TIO-HYDRAZIDE) Salts for Cancer Treatment | |
| UA106763C2 (uk) | Фуразанобензимідазоли як проліки для лікування пухлинних або аутоімунних захворювань | |
| HRP20090334T1 (en) | 3-[4-heterocyclyl-1,2,3-triazol-1-yl]-n-aryl-benzamides as inhibitors of the cytokines production for the treatment of chronic inflammatory diseases | |
| TW200738683A (en) | Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation | |
| TN2009000012A1 (en) | Amino-piperidine derivatives as cetp inhibitors | |
| RS51101B (sr) | Inhibitori hcv ns3 proteaze | |
| ES2531190T3 (es) | Método para producir un compuesto de 4-oxoquinolina | |
| EA200970486A1 (ru) | Соединения для ингибирования митоза | |
| MX2009003256A (es) | Inhibidor de la activacion de stat3/5. | |
| JO2732B1 (en) | Organic compounds | |
| RS53180B (en) | NEW SEH INHIBITORS AND THEIR USE | |
| TW200613289A (en) | Prodrugs of hiv protease inhibitors | |
| AR036053A1 (es) | Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |